Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers

Targeted inhibition plus immune checkpoint blockade: The new frontier for KRAS-mutant cancersПодробнее

Targeted inhibition plus immune checkpoint blockade: The new frontier for KRAS-mutant cancers

Resistance to MAPK pathway inhibition in BRAF mutant colorectal cancersПодробнее

Resistance to MAPK pathway inhibition in BRAF mutant colorectal cancers

Dr Scott Kopetz Deputy Chair, GI Med Oncology MD Anderson discusses KRAS-directed therapies for CRCПодробнее

Dr Scott Kopetz Deputy Chair, GI Med Oncology MD Anderson discusses KRAS-directed therapies for CRC

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant CancersПодробнее

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers

Mechanism of action of the novel KRASG12C inhibitor GDC-6036Подробнее

Mechanism of action of the novel KRASG12C inhibitor GDC-6036

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhDПодробнее

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

Strategies for Overcoming KRAS MutationsПодробнее

Strategies for Overcoming KRAS Mutations

Targeting IL-1α production through p38 MAPK inhibition in KRAS mutant Pancreatic CancerПодробнее

Targeting IL-1α production through p38 MAPK inhibition in KRAS mutant Pancreatic Cancer

Resistance in BRAF and KRAS Mutant CancersПодробнее

Resistance in BRAF and KRAS Mutant Cancers

Targeting Splice Factor Mutations - A YoshimiПодробнее

Targeting Splice Factor Mutations - A Yoshimi

Targeted Therapy for KRAS p.G12C NSCLCПодробнее

Targeted Therapy for KRAS p.G12C NSCLC

Dr. Channing Der, Ph.D. presents about Targeting KRAS for Cancer TreatmentПодробнее

Dr. Channing Der, Ph.D. presents about Targeting KRAS for Cancer Treatment

Dr. Skoulidis and Terri Conneran Discuss Treatment Strategy for Lung, Colon, and Pancreatic CancersПодробнее

Dr. Skoulidis and Terri Conneran Discuss Treatment Strategy for Lung, Colon, and Pancreatic Cancers

Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant TumorsПодробнее

Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant Tumors

Potential Synergy of MEK /PD-L1 Inhibitors in KRAS-mutant mCRCПодробнее

Potential Synergy of MEK /PD-L1 Inhibitors in KRAS-mutant mCRC

How to improve on the outcome in RAS mutant tumorsПодробнее

How to improve on the outcome in RAS mutant tumors

An introduction to the MAPK signaling pathway and pan-RAF inhibitorsПодробнее

An introduction to the MAPK signaling pathway and pan-RAF inhibitors